Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Healios KK ( (JP:4593) ) has issued an update.
Healios K.K. disclosed that a lawsuit has been filed against the company by AND medical group in the Tokyo District Court, alleging default and incomplete performance under a joint research agreement signed in April 2024 concerning the use of Healios technology and culture supernatant. AND medical group is seeking ¥120 million in damages plus litigation costs, but Healios maintains that it has properly fulfilled its contractual obligations, considers the claims entirely without merit, and intends to defend its position in court while continuing discussions with multiple partners for culture supernatant sales, stating that its current business policy remains unchanged.
The most recent analyst rating on (JP:4593) stock is a Sell with a Yen286.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
Healios K.K. is a Japan-listed biotechnology company on the Tokyo Stock Exchange Growth market (code 4593) that develops and commercializes regenerative medicine technologies. Its business includes collaboration with medical and research institutions to apply its proprietary cell and culture supernatant technologies across therapeutic and medical applications.
Average Trading Volume: 2,941,444
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen35.91B
Find detailed analytics on 4593 stock on TipRanks’ Stock Analysis page.